Accelerating Alzheimer's Research Using Advanced iPSC Platforms
As the global neuroscience community converges on the upcoming Alzheimer’s Association International Conference 2026 (AAIC 2026), the industry is bracing for a wave of high-stakes clinical data that could fundamentally redefine Alzheimer's disease therapeutics [1]. Among the anticipated updates, Biogen is expected to present Phase 2 CELIA data for diranersen (BIIB080), an investigational tau-targeting antisense oligonucleotide designed to reduce MAPT RNA and tau production, with clinical, biomarker, and safety findings in early Alzheimer’s disease [2]. Concurrently, Eisai will showcase over 50 presentations highlighting three-year real-world data and subcutaneous delivery insights for lecanemab (Leqembi®), alongside Phase 2 data for its anti-MTBR tau antibody, etalanetug [3].
These clinical advances underscore a central challenge for translational neuroscience: therapeutic concepts must be evaluated in model systems that capture human disease biology while supporting rigorous, modality-specific testing. For Alzheimer’s disease, this requires platforms that can connect patient-relevant genetics, disease-associated neuronal and glial phenotypes, quantitative biomarker readouts, and preclinical assessment of emerging modalities such as ASOs and biologics. At Cyagen, we are fueling this next generation of AD innovation.
Figure 1. Agents in clinical trials for Alzheimer’s disease (AD) treatment on the index date of January 1, 2026 [4].
Human iPSCs: Revolutionizing Alzheimer’s Disease Modeling
Human iPSC-based systems are increasingly important in this context. Induced pluripotent stem cells (iPSCs) possess the defining characteristics of embryonic stem cells, including unlimited self-renewal and the expression of key pluripotency markers such as OCT4, NANOG, and SOX2 [5]. Their ability to differentiate into virtually any cell type across all three germ layers makes iPSCs an indispensable platform for regenerative medicine, disease modeling, drug discovery, and therapeutic screening [6].
In Alzheimer's disease (AD) research, iPSC disease models address critical limitations of conventional animal models. Although transgenic rodents can reproduce specific familial AD mutations, they often fail to recapitulate hallmark human pathological features, including extensive neuronal loss and characteristic neurofibrillary tangle formation [5]. In addition, animal models cannot fully capture the complex genetic architecture of sporadic AD, which accounts for more than 95% of all cases. Patient-derived iPSCs overcome these translational barriers by preserving each patient's unique genetic background, enabling researchers to investigate the earliest molecular events underlying both familial and sporadic AD in a human cellular context.
Leveraging the intrinsic advantages of iPSC technology, we have engineered a highly streamlined workflow to develop predictive human disease models. The process initiates with the efficient reprogramming of somatic cells into a pluripotent state, seamlessly followed by precise genome engineering to introduce or correct specific AD-associated variants. Ultimately, these engineered iPSCs are directed to differentiate into distinct disease-relevant lineages, including mature cortical neurons and glial cells. This integrated approach yields physiologically accurate platforms that are purpose-built for driving disease mechanism studies, biomarker discovery, target validation, and rigorous preclinical drug screening.
Figure 2. Future direction for the investigation of AD using iPSCs [5].
Cyagen’s Isogenic iPSC Platform: From Patient Cells to Physiologically Relevant Neurons
Driven by the expanding clinical pipeline, Cyagen has developed a comprehensive, one-stop induced pluripotent stem cell (iPSC) disease modeling platform tailored for neurodegenerative research. To overcome inter-individual genetic variability, we generate perfectly matched isogenic control frameworks through a streamlined, highly validated workflow:
- Integration-Free Reprogramming: Generating stable, pluripotent iPSC lines directly from patient peripheral blood mononuclear cells (PBMCs).
- Precision Genome Editing: Engineering exact familial AD mutations (e.g., homozygous APPSwe/Swe) to mimic human pathology.
- Directed Neuronal Differentiation: Deriving mature human cortical neurons with >90% purity (NeuN/MAP2).
- Functional & Pathological Validation: Confirming robust electrophysiology (Na+/K+ currents) and hallmark AD phenotypes (elevated Aβ and p-Tau).
Figure 3. Sanger sequencing shows homozygous editing at the target site; whole exome sequencing confirms no off-target effects.
Figure 4. Robust Generation of Functional Cortical Neurons from iPSC Line
(A) Schematic of cortical neuron differentiation.
(B) Representative morphology during differentiation.
(C) Differentiated cells expressed neuronal markers NeuN and MAP2 (>90%).
(D) Patch-clamp recordings showed Na+/K+ currents and action potential firing.
Crucially, multi-dimensional phenotype validation demonstrates that the APPSwe/Swe cortical neurons successfully mirror core human AD pathologies, showing statistically significant increases in the secretion of Aβ40, Aβ42, and total amyloid-β, alongside the spontaneous upregulation of disease-relevant hyperphosphorylated Tau biomarkers, such as p-Tau181 and p-Tau217.
This fully validated platform provides drug developers and academic researchers with a highly reliable, reproducible, and translatable human genomic environment to accelerate AD mechanism studies, target validation, and high-throughput therapeutic screening.
Figure 5. APPswe cortical neurons exhibit increased AD-associated phenotypes compared with WT controls.
Preclinical Evaluation: Testing ASO Efficacy in iPSC Neurons
Beyond robust pathological validation, a true translational platform must effectively screen novel therapeutic modalities. A critical hurdle for ASO therapeutics is achieving efficient intracellular delivery in hard-to-transfect neuronal lineages, including iPSC-derived cortical neurons. Our advanced screening protocols are highly optimized to validate gymnotic free uptake, allowing therapeutic oligonucleotides to internalize naturally without the need for toxic transfection reagents. Through precisely timed incubation windows and rigorous qPCR analysis, our platform confirms distinct, dose- and time-dependent target gene knockdown. This provides biopharma developers with a biologically relevant in vitro assay to evaluate ASO structural potency and target engagement long before transitioning to costly in vivo studies.
Figure 6. Preclinical Efficacy Evaluation of ASO Free Uptake in iPSC-Derived Cortical Neurons.
End-to-End iPSC CRO Solutions: Accelerate Your Path to the Clinic
Cyagen’s end-to-end iPSC platform supports every stage of your R&D workflow, ranging from somatic cell reprogramming with a 99% success rate and advanced genome editing with up to 90% KO efficiency, to directed differentiation protocols yielding over 95% neuronal purity. As AAIC 2026 highlights a new era of Alzheimer’s breakthroughs, ensuring your preclinical data stands up to clinical scrutiny is more critical than ever. Whether you require our ready-to-use APPSwe/Swe models or custom iPSC development for novel targets, Cyagen delivers the translatable human data you need to de-risk your pipeline.
👉 Consult Our Neurobiology Experts to Design Your ASO/Biologics Screening Assay
Reference
[1] Alzheimer's Association. About | AAIC | Alzheimer's Association. AAIC website. Available at: https://aaic.alz.org/about/overview.asp. Accessed June 30, 2026.
[2] Biogen Inc. Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen. Biogen Investors website. June 29, 2026. Available at: https://investors.biogen.com/news-releases/news-release-details/biogen-highlight-breadth-alzheimers-disease-portfolio-aaic-2026. Accessed June 30, 2026.
[3] Eisai Co., Ltd. Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference® 2026 (AAIC®). Eisai Media website. June 29, 2026. Available at: https://media-us.eisai.com/2026-06-29-Eisai-to-Showcase-Alzheimers-Disease-Portfolio-with-More-Than-50-Presentations-at-the-Alzheimers-Association-International-Conference-R-2026-AAIC-R. Accessed June 30, 2026.
[4] Cummings JL, Zhou Y, Yang Y, Zhong K, Fonseca J, Osse AL, Cheng F. Alzheimer's disease drug development pipeline: 2026. Alzheimers Dement (N Y). 2026 May 5;12:e70251. doi: 10.1002/trc2.70251. PMID: 42095064; PMCID: PMC13140253.
[5] Tcw J. Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. Neurosci Lett. 2019 Apr 23;699:31-40. doi: 10.1016/j.neulet.2019.01.043. Epub 2019 Jan 24. PMID: 30685408; PMCID: PMC12872380.
[6] Valadez-Barba V, Cota-Coronado A, Hernández-Pérez OR, Lugo-Fabres PH, Padilla-Camberos E, Díaz NF, Díaz-Martínez NE. iPSC for modeling neurodegenerative disorders. Regen Ther. 2020 Dec 11;15:332-339. doi: 10.1016/j.reth.2020.11.006. PMID: 33426236; PMCID: PMC7770414.
